

1 **Title:** Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay

2

3 **Authors:** Elena Riester¹, Peter Findeisen², J. Kolja Hegel³, Michael Kabesch⁴, Andreas
4 Ambrosch⁵, Christopher M Rank⁶, Florina Langen⁶, Tina Laengin⁶, Christoph Niederhauser^{7,8}

5

6 **Affiliations:**

7 ¹Labor Augsburg MVZ GmbH, Augsburg, Germany; ²MVZ Labor Limbach, Heidelberg,
8 Germany; ³Labor Berlin, Charité Vivantes Services GmbH, Berlin, Germany; ⁴University
9 Children's Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John
10 and the University Hospital, University of Regensburg, Germany; ⁵Institute for Laboratory
11 Medicine, Microbiology and Hygiene, Barmherzige Brüder Hospital, Regensburg, Germany;
12 ⁶Roche Diagnostics GmbH, Penzberg, Germany; ⁷Interregionale Blood Transfusion Swiss Red
13 Cross, Bern, Switzerland; ⁸Institute for Infectious Diseases (IFIK), University of Bern, Bern,
14 Switzerland

15

16 ***Corresponding author**

17 Christoph Niederhauser, Interregionale Blood Transfusion Swiss Red Cross, Murtenstrasse
18 133, 3008 Bern, Switzerland, Christoph.Niederhauser@itransfusion.ch

19

20 **Running Title:** Evaluation of the Elecsys Anti-SARS-CoV-2 S assay

21 **Key words:** SARS-CoV-2, spike protein, nucleocapsid protein, immunoassay, antibodies

22

23 **Abstract**

24 Background: The Elecsys[®] Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics
25 International Ltd, Rotkreuz, Switzerland) has been developed for the *in vitro* quantitative
26 detection of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
27 2) spike (S) protein. We evaluated the performance of this assay using samples from seven
28 sites in Germany, Austria, and Switzerland.

29

30 Methods: Anonymized frozen, residual serum, or plasma samples from blood donation
31 centers or routine diagnostic testing were used for this study. For specificity and sensitivity
32 analyses, presumed negative samples collected before October 2019 and SARS-CoV-2 PCR-
33 confirmed single or sequential samples were tested, respectively. The performance of the
34 Elecsys Anti-SARS-CoV-2 S immunoassay was also compared with other commercial
35 immunoassays.

36

37 Results: The overall specificity (n=7880 pre-pandemic samples) and sensitivity (n=240 PCR-
38 positive samples [≥ 14 days post-PCR]) for the Elecsys Anti-SARS-CoV-2 S immunoassay
39 were 99.95% (95% confidence interval [CI]: 99.87–99.99) and 97.92% (95% CI: 95.21–
40 99.32), respectively. Compared with seven other immunoassays, the Elecsys Anti-SARS-CoV-
41 2 S assay had comparable or greater specificity and sensitivity. The Elecsys Anti-SARS-CoV-2
42 S immunoassay had significantly higher specificity compared with the LIAISON[®] SARS-CoV-2
43 S1/S2 IgG, ADVIA Centaur[®] SARS-CoV-2 Total, ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-
44 CoV-2 IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays, and significantly higher
45 sensitivity (≥ 14 days post-PCR) compared with the ARCHITECT SARS-CoV-2 IgG, iFlash-
46 SARS-CoV-2 IgG and IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG assays.

47

48 Conclusion: The Elecsys Anti-SARS-CoV-2 S assay demonstrated a robust and favorable
49 performance across samples from multiple European sites, with a very high specificity and
50 sensitivity for the detection of anti-S antibodies.

51 **Introduction**

52 In December 2019 a novel coronavirus emerged (1), named severe acute respiratory
53 syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of the disease, COVID-
54 19 (2, 3). SARS-CoV-2 is an enveloped, single-stranded RNA virus of the family
55 Coronaviridae; its genome encodes 16 nonstructural proteins and four structural proteins:
56 spike (S), envelope (E), membrane (M), and nucleocapsid (N) (4). The most prominent
57 protein component on the viral surface is the S glycoprotein – a large transmembrane
58 protein that assembles into trimers to form the distinctive surface spikes of coronaviruses (5,
59 6). Each S monomer consists of two subunits, S1 and S2, which mediate receptor binding
60 (via the receptor-binding domain [RBD] located in S1) and membrane fusion, respectively,
61 leading to entry into host cells (6-8).

62
63 Following infection with SARS-CoV-2, the host mounts an immune response against the
64 virus, including production of specific antibodies against viral antigens (9). Understanding
65 the dynamics of the antibody response to the virus is critical in establishing a relevant time
66 window to use for serology testing (9). Studies into the kinetics of antibodies to SARS-CoV-2
67 are rapidly emerging and, based on current evidence, both immunoglobulin M (IgM) and G
68 (IgG) antibodies have been detected as early as day 0 to 5 after symptom onset (10, 11).
69 The chronological order of appearance and levels of IgM and IgG appears to be highly
70 variable and often simultaneous (12-14). Several studies have observed median
71 seroconversion at day 10–13 after symptom onset for IgM and day 12–15 for IgG, with
72 maximum seroconversion for IgM, IgG, and total antibodies occurring at week 2–3, week 2–
73 4, and around week 2, respectively (13-16).

74
75 Emergence of the COVID-19 pandemic has resulted in an urgent and unmet need to develop
76 reliable serological tests to determine past exposure to the virus and the seroprevalence in a
77 given population (17). This information is crucial to support diagnosis, contact tracing,
78 epidemiology studies, and vaccine development to enable characterization of pre-vaccination
79 immune status and vaccine-induced immune response (9, 18-20). There are currently 242
80 candidate SARS-CoV-2 vaccines in development (21) and, of these, 10 are currently in early,
81 limited, or fully approved use (status February 09, 2021) (22). The majority of the vaccines
82 in use are based on the S protein, with the goal of eliciting protective neutralizing
83 antibodies; the rest are based on whole inactivated SARS-CoV-2 (23, 24). Serology assays
84 are also needed for the identification of neutralizing antibodies from convalescent plasma
85 donors (25).

86

87 The Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics International Ltd, Rotkreuz,
88 Switzerland) is an electrochemiluminescence immunoassay (ECLIA), which has been
89 developed for the *in vitro* quantitative detection of antibodies, including IgG, against the
90 SARS-CoV-2 S protein RBD in human serum and plasma (26).

91

92 The objective of this multicenter European study was to evaluate the specificity and
93 sensitivity of the Elecsys Anti-SARS-CoV-2 S immunoassay using pre-pandemic samples
94 (from routine diagnostics or blood donation) and PCR-positive samples, respectively, as well
95 as compare the performance of this quantitative test with other commercially available
96 immunoassays in terms of specificity and sensitivity.

97

98 **Materials and methods**

99 *Study design*

100 The study was executed from August 17, 2020 to September 1, 2020 with samples tested at
101 four European sites: Labor Augsburg MVZ GmbH, Augsburg, Germany; MVZ Labor Dr.
102 Limbach & Kollegen GbR, Heidelberg, Germany; Interregionale Blutspende SRK AG (SRK
103 Bern), Bern, Switzerland; and Krankenhaus Barmherzige Brüder, Regensburg, Germany.
104 Samples were collected from those four sites, as well as from three additional sites: Labor
105 Berlin – Charité Vivantes GmbH, Berlin, Germany; Tirol Kliniken, Innsbruck, Austria; and
106 Deutsches Rotes Kreuz Blutspendedienst West, Hagen, Germany.

107

108 Samples from Augsburg and Heidelberg included those referred to the respective study site
109 by physicians. Heidelberg also tested samples from employees and hospitalized patients,
110 including a subset from patients receiving dialysis. All samples provided by the study site in
111 Berlin were collected from hospitalized patients, including a subset from patients monitored
112 in the intensive care unit (ICU). Samples tested in Regensburg were taken from employees
113 and pediatric patients referred to the site by physicians.

114

115 These samples were collected and tested in accordance with applicable regulations,
116 including relevant European Union directives and regulations, and the principles of the
117 Declaration of Helsinki. All samples from Augsburg, Heidelberg, Berlin, and Hagen were
118 anonymized. A statement was obtained from the Ethics Committee (EC) of the
119 Landesärztekammer Bayern confirming that there are no objections to the use of
120 anonymized leftover samples. From the internal EC at the study site in Bern (Switzerland) a

waiver was received and from the internal EC at the study site in Innsbruck (Austria) an approval was received. For Regensburg (Germany), EC approvals were already in place, amendments were submitted to notify the EC about Elecsys Anti-SARS-CoV-2 S testing. At Augsburg, Heidelberg, and Bern the assays were performed on the cobas e 801 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland), whereas at Regensburg the assays were performed on the cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland).

Serum and plasma samples

Anonymized frozen, residual samples from blood donation centers or routine laboratory diagnostics, as well as banked samples, were used for this study. For specificity analysis of the Elecsys Anti-SARS-CoV-2 S assay, 7880 presumed negative samples (5056 blood donor and 2824 diagnostic routine samples) that were collected before October 2019 were tested. The diagnostic routine cohort included samples from pregnancy screening and pediatrics. For the sensitivity analysis of the Elecsys Anti-SARS-CoV-2 S assay, 827 PCR-confirmed single or sequential samples from 272 different patients, with known time difference between blood draw and positive PCR test, were tested. Of these presumed negative and PCR-confirmed samples, 7903 were tested on the commercially available Elecsys[®] Anti-SARS-CoV-2 assay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) (27). Additionally, a number of these samples were tested on other commercially available assays: LIAISON[®] SARS-CoV-2 S1/S2 IgG (DiaSorin) (28), 2052 samples; EUROIMMUN Anti-SARS-CoV-2 IgG (29) and IgA assays (EUROIMMUN) (30), 1618 and 1624 samples, respectively; ARCHITECT SARS-CoV-2 IgG (Abbott) (31), 3068 samples; ADVIA Centaur[®] SARS-CoV-2 Total (Siemens Healthineers) (32), 1064 samples; iFlash-SARS-CoV-2 IgG and IgM assays (Shenzhen YHLO Biotech Co) (33), both 1062 samples.

Elecsys Anti-SARS-CoV-2 S assay

The Elecsys Anti-SARS-CoV-2 S immunoassay is a quantitative ECLIA that detects high-affinity antibodies to the SARS-CoV-2 S protein RBD and has a low risk of detecting weakly cross-reactive and unspecific antibodies. Results are automatically reported as the analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as negative for anti-SARS-CoV-2 S antibodies and ≥0.80 U/mL interpreted as positive for anti-SARS-CoV-2 S antibodies (Roche Diagnostics GmbH. Elecsys Anti-SARS-CoV-2 S assay method sheet. 2020; version 01) (26).

Comparator assays

Specimens were analyzed using eight comparator immunoassays according to the manufacturer's instructions. Interpretation of results was performed according to the manufacturer's instructions.

The Elecsys Anti-SARS-CoV-2 assay is an ECLIA for the *in vitro* qualitative detection of antibodies, including IgG, against SARS-CoV-2, using a recombinant protein representing the nucleocapsid (N) antigen (27). Results are automatically calculated in the form of a cutoff index (COI), with COI values <1.0 interpreted as non-reactive (negative) for anti-SARS-CoV-2 N antibodies and ≥ 1.0 as reactive (positive) for anti-SARS-CoV-2 N antibodies (27).

The LIAISON SARS-CoV-2 S1/S2 IgG assay is an indirect chemiluminescence immunoassay (CLIA) for the quantitative detection of IgG anti-S1 and IgG anti-S2 antibodies to SARS-CoV-2 (28). Results are automatically calculated, with antibody concentrations expressed as arbitrary units (AU/mL). Concentrations of <12.0 AU/mL are interpreted as negative, ≥ 12.0 to <15.0 AU/mL are interpreted as equivocal, and ≥ 15.0 AU/mL are interpreted as positive (28). Equivocal values are referred to as 'gray zone' results.

The EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays are separate enzyme-linked immunosorbent assay (ELISAs) that detect IgG or IgA anti-S1 antibodies to SARS-CoV-2 (29, 30). Results are evaluated semi-quantitatively by calculation of a ratio in which the absorbance values of the controls or patient samples are related to the absorbance value of the calibrator (29, 30). For both assays, ratio results <0.8 are interpreted as negative, ≥ 0.8 to <1.1 are borderline, and ≥ 1.1 are positive (29, 30). Borderline values are referred to as 'gray zone' results.

The ARCHITECT SARS-CoV-2 IgG assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgG antibodies against the N antigen (31). Results are expressed in signal-to-cutoff (S/CO) values, with <1.4 results interpreted as negative and ≥ 1.4 results interpreted as positive (31).

The ADVIA Centaur SARS-CoV-2 Total assay is a CLIA intended for the qualitative detection of antibodies against the RBD of the S1 protein (32). Results are reported in index values, with <1.0 interpreted as non-reactive (negative) for anti-SARS-CoV-2 antibodies and ≥ 1.0 interpreted as reactive (positive) for anti-SARS-CoV-2 antibodies (32).

The iFlash-SARS-CoV-2 IgM and IgG assays (33) are separate CLIAs used for the qualitative detection of IgM or IgG against the S and N proteins. The iFlash system automatically calculates the analytic concentration of each sample, with <10 AU/mL interpreted as non-reactive and ≥ 10 AU/mL interpreted as reactive for anti-SARS-CoV-2 IgM or IgG antibodies.

Statistical analysis

Sample size estimations for specificity and sensitivity analyses were based on formulae proposed previously (34). Assuming specificities between 0.998 and 0.999 and a sensitivity of 0.999, samples sizes of 1698 to 20964 and 32 to 50 respectively, would be required to obtain a significance level of 0.05 and a power of 0.8. For specificity and sensitivity calculations, point estimates and two-sided 95% confidence intervals (CIs) using the exact method were computed employing R version 3.4.0 (35). In the sensitivity evaluation, assay results were assigned to the respective week after positive PCR result. In the comparison with other commercially available assays, only samples with paired measurements were included in the respective analyses. For the differences in estimated specificities and sensitivities between Elecsys Anti-SARS-CoV-2 S assay and the comparator assays, two-sided 95% Wald CIs were calculated as previously recommended (36). If these CIs did not include zero, differences were considered as statistically significant.

Data availability

Qualified researchers may request access to individual patient level data through the clinical study data request platform (<https://vivli.org/>). Further details on Roche's criteria for eligible studies are available here: <https://vivli.org/members/ourmembers/>. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm.

Results

Overall performance of the Elecsys Anti-SARS-CoV-2 S assay

Specificity in different target cohorts

Specificity of the Elecsys Anti-SARS-CoV-2 S assay was evaluated at three European sites (with samples from five European sites) using 7880 evaluable residual samples from blood donors and routine diagnostic testing; all of which were collected before October 2019 and

presumed negative for SARS-CoV-2 antibodies. The overall specificity for all samples was 99.95% (95% CI: 99.87–99.99) (Table 1). There were four samples with reactive results of 1.790 U/mL, 0.900 U/mL, 0.870 U/mL, and 1.130 U/mL. Three of these reactive samples were from blood donor samples, of which one was collected in March 2016 (influenza season) at Innsbruck, Austria and two were collected in July/August 2018 (outside influenza season) at Bern, Switzerland (Table 1). There was no statistically significant difference in specificity between blood donor samples collected during or outside influenza season. The other reactive sample was from the pregnancy screening cohort in Augsburg (Table 1).

Sensitivity in different target cohorts

In total, 827 evaluable single and sequential samples from 272 SARS-CoV-2 PCR-confirmed patients were evaluated at three European sites (with samples from four European sites). The time span of samples collected after positive PCR was between day 0 and day 120. For subjects with sequential blood draws with more than one sample per time interval, only the result of the last blood draw per given time interval was used for the respective sensitivity calculation. The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay ≥ 14 days post-PCR (n=240) was 97.92% (95% CI: 95.21–99.32) (Table 2a). The resulting site-specific sensitivities for Augsburg, Berlin, Heidelberg, and Regensburg samples collected ≥ 14 days post-PCR confirmation were 100.00% (95% CI: 95.89–100.00), 100.00% (95% CI: 91.40–100.00), 98.72% (95% CI: 93.06–99.97%), and 87.88% (95% CI: 71.80–96.60), respectively (Table 2b).

Visualization of seroconversions and/or titer visualization

For all subjects with at least two sequential blood draws, trajectories were plotted to visualize antibody titer development from day 0 to 78 post-PCR-positive test (Figure 1). Most trajectories show a rapid increase in antibody titer and no considerable decline of antibody titer can be seen for the early and later blood draws. Once detected reactive, none of the subsequent samples drawn per subject showed a decline of titer below the cutoff.

Comparison with Elecsys Anti-SARS-CoV-2 assay

A direct method comparison between the Elecsys Anti-SARS-CoV-2 S assay and the commercially available Elecsys Anti-SARS-CoV-2 assay was performed. This included a total of 7903 samples comprising both confirmed positive samples from sensitivity testing and presumed positive samples with at least one positive antibody result (n=1011), as well as presumed negative samples from specificity testing cohort samples (n= 6892: n=4068 blood

donors; n=2824 routine diagnostic). For all samples, the overall percent agreement (OPA) between the Elecsys Anti-SARS-CoV-2 S assay and the Elecsys Anti-SARS-CoV-2 assay was 99.30% (95% CI: 99.10–99.48) (Table S1a). For presumed negative samples and confirmed positive samples, the negative percent agreement (NPA) and positive percent agreement (PPA), respectively, between the S- and N-assays were >99% (Table S1b–c).

Comparison with other commercially available assays

The performance of the Elecsys Anti-SARS-CoV-2 S immunoassay was compared with seven other commercially available SARS-CoV-2 assays, and sensitivity and specificity results, along with percent agreement, were recorded.

The OPA between the Elecsys Anti-SARS-CoV-2 S assay and other comparator tests was recorded (Table S2). The Elecsys Anti-SARS-CoV-2 S test had the highest OPA with the ARCHITECT SARS-CoV-2 IgG (N-assay), at 99.19% (95% CI: 98.80–99.47), and the lowest OPA with the ADVIA Centaur SARS-CoV-2 Total (S-assay), at 88.25% (95% CI: 86.16–90.13) (Table S2).

Specificity

The specificity of the Elecsys Anti-SARS-CoV-2 S assay was comparable or higher than the specificity of all tested comparator assays (Table 3). The specificity of the Elecsys Anti-SARS-CoV-2 S test was significantly higher compared with the LIAISON SARS-CoV-2 S1/S2 IgG, ADVIA Centaur SARS-CoV-2 Total, ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-CoV-2 IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays (Table S3a). No statistically significant difference was observed between the specificity of the Elecsys Anti-SARS-CoV-2 S assay compared with the iFlash-SARS-CoV-2 IgG assay (Table S3a).

Sensitivity

The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay for detecting seropositive results was compared with six comparator assays; analysis compared with the LIAISON SARS-CoV-2 S1/S2 IgG test could not be performed due to a small sample size. Sensitivity was recorded for samples collected between 0–6, 7–13, and ≥14 days post-PCR-positive test. The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay was equal to or higher than the sensitivity for all tested IgM, IgG, and total antibody assays at all time intervals (Table 4). The EUROIMMUN Anti-SARS-CoV-2 IgA assay showed a higher sensitivity in the 0–6 and 7–13 days post-PCR time intervals and a lower sensitivity in the ≥14 days post-PCR time interval

compared with the Elecsys Anti-SARS-CoV-2 S assay (Table 4). The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay at detecting antibodies ≥ 14 days post-PCR was significantly higher compared with the ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-CoV-2 IgG and IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG assays (Table S3b).

Discussion

Due to the COVID-19 pandemic, there is a pressing need to develop highly specific and sensitive serology tests to assist with the diagnosis of, and to reveal past exposure to, the SARS-CoV-2 virus (17), as well as to support the development of vaccines through distinguishing natural infection-induced immunity from vaccine-induced immunity (9, 18). This was the first multicenter study to demonstrate the performance of the automated Elecsys Anti-SARS-CoV-2 S immunoassay, which detects antibodies against the SARS-CoV-2 S protein RBD. Antibodies against the RBD have previously been shown to correlate strongly with protective neutralizing antibodies (37).

The results from our study revealed that the Elecsys Anti-SARS-CoV-2 S immunoassay displays a robust and favorable performance under routine conditions at multiple sites in Europe, with a very high specificity (99.95%) and sensitivity (97.92%) for the detection of anti-S antibodies. The point estimates for specificity and sensitivity are comparable to the values reported in the package insert of the Elecsys Anti-SARS-CoV-2 S assay (99.98% and 98.8%, respectively) (26). In addition, the Elecsys Anti-SARS-CoV-2 S assay showed a performance comparable with the commercially available Elecsys Anti-SARS-CoV-2 (N-assay), with 95% CIs that overlap (99.69–99.88% for specificity and 97.0–100% for sensitivity); both assays had a very high overall percent agreement. The Elecsys Anti-SARS-CoV-2 assay has a previously reported specificity and sensitivity ≥ 14 days post-confirmation of 99.8% and 99.5%, respectively (38).

The overall specificity of $>99.9\%$ determined in this study demonstrated that the Elecsys Anti-SARS-CoV-2 S is a highly specific assay for the detection of antibodies against SARS-CoV-2. Notably, this analysis included 2424 samples from pregnant women and pediatric populations. The availability of an accurate SARS-CoV-2 serology assay is particularly important for the pregnant population, considering the changes in the immune system that occur during pregnancy, which may increase the woman's susceptibility to severe infection (39). Additionally, an antibody assay with a high specificity is imperative to reduce the risk of false-positive results, which may inaccurately indicate a past SARS-CoV-2 infection (40).

The Elecsys Anti-SARS-CoV-2 S immunoassay demonstrated good specificity and sensitivity in direct comparison with other commercially available assays; both performance measurements were equal to or greater than those for all other evaluated comparator assays. These other assays have also been assessed in previous studies (17, 41-44). However, it is important to note that, for a direct comparison of sensitivity, the available assays differ with respect to assay designs (e.g. antibody classes used) as well as the targets (anti-N and anti-S) that they detect.

A multicenter comparison of seven serology assays, including the Elecsys Anti-SARS-CoV-2 assay, revealed a subpopulation of PCR-confirmed SARS-CoV-2 individuals who were persistently seronegative, which represents a proportion of patients that may be at risk for re-infection (45). Within the group of PCR-confirmed samples in our study, for which there was at least one S and one N antibody result from another comparator assay, there were samples from five patients all of which had a reactive Elecsys Anti-SARS-CoV-2 S test result, a reactive or 'gray zone' EUROIMMUN test result and a reactive ADVIA Centaur test result (S-assays), and a non-reactive Elecsys Anti-SARS-CoV-2 and ARCHITECT SARS-CoV-2 IgG test result (N-assays). There was only one sample that was commonly non-reactive in all S-based assays and reactive in all N-based assays. However, the blood draw was taken very early, at the same day as the PCR was done, and the follow-up sample was reactive with the Elecsys Anti-SARS-CoV-2 S assay. Data indicating differences in the kinetics of serology assays are ambiguous and there is little difference in the timing of these responses (42, 46-49). However, differences between N- and S- antigen-based assays should be taken into consideration when interpreting results.

A major strength of this study is the large cohort of presumed negative samples from multiple sites used to determine the specificity of the assay, as well as the multiple method comparison analyses performed and the various population cohorts used, with samples from pediatric and pregnant woman. Further studies should be performed to determine the sensitivity of the Elecsys Anti-SARS-CoV-2 S immunoassay on a larger sample group.

Conclusion

This study demonstrated the performance of the Elecsys Anti-SARS-CoV-2 S immunoassay, with a very high specificity of 99.95% and sensitivity of 97.92% in samples ≥ 14 days post-PCR confirmation, which was equal to or greater than the performance of seven other

commercially available immunoassays. Therefore, these data support the use of the Elecsys Anti-SARS-CoV-2 S immunoassay for reliable identification of past exposure to SARS-CoV-2 in various populations, and highlight the potential for the use of this assay in determining immune status during vaccine efficacy studies.

Funding

This study was funded by Roche Diagnostics GmbH (Mannheim, Germany).

Conflicts of interest

ER and AA report grants from Roche Diagnostics, during the conduct of the study and personal fees from Roche Diagnostics (honoraria for lectures), outside the submitted work. MK reports non-financial support from Roche Diagnostics, during the conduct of the study. CN, PF and JKH have nothing to disclose. FL, CMR, and TL are employees of Roche Diagnostics GmbH.

Acknowledgements

The authors would like to acknowledge: Kathrin Schoenfeld (Roche Diagnostics) for her role in study conceptualization, study management, interpretation of analysis, and further critical input; Michael Laimighofer (Roche Diagnostics) for his role in database generation and data validation, statistical analysis plan, and formal analysis; and Sigrid Reichhuber and Janina Edion (Roche Diagnostics) for their role in investigational site management, data acquisition, and study monitoring. Medical writing support was provided by Katie Farrant, Elements Communications Ltd, Westerham, UK and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland. ELECSYS and COBAS E are trademarks of Roche Diagnostics. All other product names and trademarks are the property of their respective owners.

References

1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 395:514–523.
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. 2020. A new coronavirus associated with human respiratory disease in China. *Nature* 579:265–269.
3. World Health Organization. 2020. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020>. Accessed February 26 2021.
4. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, Atif SM, Hariprasad G, Hasan GM, Hassan MI. 2020. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. *Biochim Biophys Acta Mol Basis Dis* 1866:165878.
5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 181:281–292 e6.
6. Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. 2020. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. *Antiviral Res* 178:104792.
7. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 367:1260–1263.
8. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* 11:1620.
9. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. 2020. Humoral responses and serological assays in SARS-CoV-2 infections. *Front Immunol* 11:610688.
10. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z, Zheng S. 2020. Evaluation of nucleocapsid and spike protein-based enzyme-linked

- 426 immunosorbent assays for detecting antibodies against SARS-CoV-2. *J Clin Microbiol*
427 58.
- 428 11. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y,
429 Zhang L, Han L, Dang S, Xu Y, Yang QW, Xu SY, Zhu HD, Xu YC, Jin Q, Shama L,
430 Wang L, Wang J. 2020. Profiling early humoral response to diagnose novel
431 coronavirus disease (COVID-19). *Clin Infect Dis* 71:778–785.
- 432 12. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM,
433 Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo
434 CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. 2020. Temporal profiles
435 of viral load in posterior oropharyngeal saliva samples and serum antibody responses
436 during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*
437 20:565–574.
- 438 13. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF,
439 Wang DQ, Hu Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG,
440 Hu L, Zhang XX, Xiang JL, Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui XP, Zhou Z,
441 Zhu MM, Wang J, Xue CJ, Li XF, Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ,
442 Zhang Y, Liu XM, Li JJ, Zhang DC, Zhang F, Liu P, Yuan J, Li Q, Hu JL, Chen J, et al.
443 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*
444 26:845–848.
- 445 14. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S,
446 Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang
447 J, Xia N, Zhang Z. 2020. Antibody responses to SARS-CoV-2 in patients with novel
448 coronavirus disease 2019. *Clin Infect Dis* 71:2027–2034.
- 449 15. Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W, Yu F, Ge SX, Zou QD, Yuan Q, Lin S,
450 Hong CM, Yao XY, Zhang XJ, Wu DH, Zhou GL, Hou WH, Li TT, Zhang YL, Zhang SY,
451 Fan J, Zhang J, Xia NS, Chen Y. 2020. Serology characteristics of SARS-CoV-2
452 infection after exposure and post-symptom onset. *Eur Respir J* 56.
- 453 16. Young BE, Ong SWX, Ng LFP, Anderson DE, Chia WN, Chia PY, Ang LW, Mak TM,
454 Kalimuddin S, Chai LYA, Pada S, Tan SY, Sun L, Parthasarathy P, Fong SW, Chan YH,
455 Tan CW, Lee B, Röttschke O, Ding Y, Tambyah P, Low JGH, Cui L, Barkham T, Lin
456 RTP, Leo YS, Renia L, Wang LF, Lye DC. 2020. Viral dynamics and immune correlates
457 of COVID-19 disease severity. *Clin Infect Dis* doi:10.1093/cid/ciaa1280.
- 458 17. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. 2020. Antibody tests in
459 detecting SARS-CoV-2 infection: A meta-analysis. *Diagnostics (Basel)* 10:319.

- 460 18. Ernst E, Wolfe P, Stahura C, Edwards KA. 2021. Technical considerations to
461 development of serological tests for SARS-CoV-2. *Talanta* 224:121883.
- 462 19. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang
463 WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J,
464 Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W.
465 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored
466 COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-
467 blind, placebo-controlled, phase 2 trial. *Lancet* 396:479–488.
- 468 20. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell
469 JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-
470 Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J,
471 Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE,
472 Mascola JR, Graham BS, Beigel JH. 2021. Durability of Responses after SARS-CoV-2
473 mRNA-1273 Vaccination. *N Engl J Med* 384:80–82.
- 474 21. World Health Organization. 2021. The COVID-19 candidate vaccine landscape.
475 [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
476 [vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines). Accessed February 09 2021.
- 477 22. The New York Times. 2021. Coronavirus vaccine tracker.
478 <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>.
479 Accessed February 09 2021.
- 480 23. Dai L, Gao GF. 2020. Viral targets for vaccines against COVID-19. *Nat Rev Immunol*
481 doi:10.1038/s41577-020-00480-0.
- 482 24. Forni G, Mantovani A. 2021. COVID-19 vaccines: where we stand and challenges
483 ahead. *Cell Death Differ* doi:10.1038/s41418-020-00720-9:1-14.
- 484 25. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, Wei P, Ge J, Gou M, Li X, Sun L,
485 Cao T, Wang P, Zhou C, Zhang R, Liang P, Guo H, Wang X, Qin CF, Chen F, Dong C.
486 2020. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19
487 convalescent individuals. *Immunity* 52:971–977 e3.
- 488 26. Roche Diagnostics GmbH. 2020. Elecsys® Anti-SARS-CoV-2 S assay method sheet;
489 V1. [https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-](https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2-s.html)
490 [2-s.html](https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2-s.html). Accessed February 26 2021.
- 491 27. Roche Diagnostics GmbH. 2020. Elecsys® Anti-SARS-CoV-2 assay method sheet;
492 09203095501 V6.0. <https://www.fda.gov/media/137605/download>. Accessed
493 February 26 2021.

- 494 28. DiaSorin. 2020. LIAISON® SARS-CoV-2 S1/S2 IgG assay method sheet;
495 M0870004366/D 09/20.
496 [https://www.diasorin.com/sites/default/files/allegati_prodotti/covid_-](https://www.diasorin.com/sites/default/files/allegati_prodotti/covid_-_brochure_igg_unica_m0870004366-d_low.pdf)
497 [brochure_igg_unica_m0870004366-d_low.pdf](https://www.diasorin.com/sites/default/files/allegati_prodotti/covid_-_brochure_igg_unica_m0870004366-d_low.pdf). Accessed February 26 2021.
- 498 29. EUROIMMUN. 2020. Anti-SARS-CoV-2 ELISA (IgG) product data sheet;
499 EI_2606_D_UK_A06, 10/2020. [https://www.coronavirus-](https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_A.pdf)
500 [diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_A.pdf](https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_A.pdf)
501 . Accessed February 26 2021.
- 502 30. EUROIMMUN. 2020. Anti-SARS-CoV-2 ELISA (IgA) product data sheet;
503 EI_2606_D_UK_B04, 10/2020. [https://www.coronavirus-](https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_B.pdf)
504 [diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_B.pdf](https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_B.pdf)
505 . Accessed February 26 2021.
- 506 31. Abbott. 2020. ARCHITECT SARS-CoV-2 IgG assay method sheet.
507 <https://www.fda.gov/media/137383/download>. Accessed February 26 2021.
- 508 32. Siemens. 2020. ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay method sheet;
509 11206904_EN Rev. 01, 2020-05. <https://www.fda.gov/media/138446/download>.
510 Accessed February 26 2021.
- 511 33. Shenzhen YHLO Biotech Co Ltd. 2020. iFlash-SARS-CoV-2 IgM/IgG antibody test
512 product overview. [http://en.szyhlo.com/cmscontent/iFlash-SARS-CoV-2-IgMIgG-](http://en.szyhlo.com/cmscontent/iFlash-SARS-CoV-2-IgMIgG-Antibody-Test-439.html)
513 [Antibody-Test-439.html](http://en.szyhlo.com/cmscontent/iFlash-SARS-CoV-2-IgMIgG-Antibody-Test-439.html). Accessed February 26 2021.
- 514 34. Hajian-Tilaki K. 2014. Sample size estimation in diagnostic test studies of biomedical
515 informatics. J Biomed Inform 48:193–204.
- 516 35. R Core Team. 2017. R: A language and environment for statistical computing. R
517 Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.
518 Accessed February 26 2021.
- 519 36. Wenzel D, Zapf A. 2013. Difference of two dependent sensitivities and specificities:
520 Comparison of various approaches. Biom J 55:705–718.
- 521 37. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A,
522 Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael
523 N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH,
524 Schmitz J, Baric RS, de Silva AM. 2020. The receptor binding domain of the viral
525 spike protein is an immunodominant and highly specific target of antibodies in SARS-
526 CoV-2 patients. Sci Immunol 5.
- 527 38. Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl M,
528 Sadlowski H, Sachse C, Torriani G, Eckerle I, Riedel A. 2020. Development and

validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for
determining past exposure to SARS-CoV-2. *J Clin Microbiol* 58.

39. Dashraath P, Wong JIJ, Lim MXK, Lim LM, Li S, Biswas A, Choolani M, Mattar C, Su
LL. 2020. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J
Obstet Gynecol* 222:521–531.

40. Farnsworth CW, Anderson NW. 2020. SARS-CoV-2 serology: much hype, little data.
Clin Chem 66:875–877.

41. Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, Zimmer G, Agoritsas
T, Stirnemann J, Spechbach H, Guessous I, Stringhini S, Pugin J, Roux-Lombard P,
Fontao L, Siegrist CA, Eckerle I, Vuilleumier N, Kaiser L, Geneva Center for Emerging
Viral D. 2020. Validation of a commercially available SARS-CoV-2 serological
immunoassay. *Clin Microbiol Infect* 26:1386–1394.

42. Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau HF. 2020. Brief clinical evaluation
of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol* 129:104480.

43. Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM,
Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D,
Houhou-Fidouh N, Reusken C, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL.
2020. Severe acute respiratory syndrome coronavirus 2-specific antibody responses
in coronavirus disease patients. *Emerg Infect Dis* 26:1478–1488.

44. Ocmant A, Roisin S, De Meuter R, Brauner J. 2021. Clinical performance of the Advia
Centaur anti-SARS-CoV-2 chemiluminescent immunoassay related to antibody
kinetics. *J Med Virol* doi:10.1002/jmv.26800.

45. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, Shenhar Y,
Payorsky I, Cohen Y, Kohn Y, Indenbaum V, Lazar R, Geylis V, Oikawa MT, Shinar E,
Stoyanov E, Keinan-Boker L, Bassal R, Reicher S, Yishai R, Bar-Chaim A, Doolman R,
Reiter Y, Mendelson E, Livneh Z, Freedman LS, Lustig Y. 2020. Multi-center
nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-
responding seronegative subpopulation. *EClinicalMedicine* 29:100651.

46. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR, Chertow
DS, Davey RT, Jr., Cohen JI. 2020. Detection of nucleocapsid antibody to SARS-CoV-
2 is more sensitive than antibody to spike protein in COVID-19 patients. *medRxiv*
doi:10.1101/2020.04.20.20071423.

47. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, Song T, Alshukairi AN, Chen R,
Zhang Z, Gan M, Zhu A, Huang Y, Luo L, Mok CKP, Al Gethamy MM, Tan H, Li Z,
Huang X, Li F, Sun J, Zhang Y, Wen L, Li Y, Chen Z, Zhuang Z, Zhuo J, Chen C,

564 Kuang L, Wang J, Lv H, Jiang Y, Li M, Lin Y, Deng Y, Tang L, Liang J, Huang J,
565 Perlman S, Zhong N, Zhao J, Malik Peiris JS, Li Y, Zhao J. 2020. Kinetics of viral load
566 and antibody response in relation to COVID-19 severity. J Clin Invest 130:5235–
567 5244.

568 48. Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E,
569 Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, Andre E, Van Ranst M,
570 Lagrou K, Vermeersch P. 2020. Antibody response against SARS-CoV-2 spike protein
571 and nucleoprotein evaluated by four automated immunoassays and three ELISAs.
572 Clin Microbiol Infect 26:1557 e1–1557 e7.

573 49. Johnson M, Wagstaffe HR, Gilmour KC, Mai AL, Lewis J, Hunt A, Sirm J, Bengt C,
574 Grandjean L, Goldblatt D. 2020. Evaluation of a novel multiplexed assay for
575 determining IgG levels and functional activity to SARS-CoV-2. J Clin Virol
576 130:104572.
577

578 **Table 1. Specificity results for the Elecsys Anti-SARS-CoV-2 S assay**

Sample cohort		Number of	Reactive	Specificity (95% confidence
		samples	samples	intervals, 2-sided)
Blood donors				
Origin / season	Innsbruck / influenza season	1050	1	99.90% (99.47–100.00)
	Hagen / no seasonal selection	955	0	100.00% (99.61–100.00)
	Bern / outside influenza season	2000	2	99.90% (99.64–99.99)
	Bern / influenza season	1051	0	100.00% (99.65–100.00)
Total blood donors		5056	3	99.94% (99.83–99.99)
Diagnostic routine				
Origin / cohort	Augsburg / diagnostic routine	400	0	100.00% (99.08–100.00)
	Augsburg / pregnancy screening	1496	1	99.93% (99.63–100.00)
	Heidelberg / pregnancy screening	737	0	100.00% (99.50–100.00)
	Heidelberg / pediatric samples	191	0	100.00% (98.09–100.00)
Total diagnostic routine		2824	1	99.96% (99.80–100.00)
Overall (all samples)		7880	4	99.95% (99.87–99.99)

579

Table 2a. Overall sensitivity results for the Elecsys Anti-SARS-CoV-2 S assay

Days post-PCR-positive test	Number of samples	Reactive samples	Non-reactive samples	Sensitivity (95% confidence intervals, 2-sided)
0 to 6	44	25	19	56.82% (41.03–71.65)
7 to 13	49	42	7	85.71% (72.76–94.06)
14 to 20	47	46	1	97.87% (88.71–99.95)
21 to 27	58	58	0	100.00% (93.84–100.00)
28 to 34	43	43	0	100.00% (91.78–100.00)
35 to 41	57	56	1	98.25% (90.61–99.96)
42 to 48	47	47	0	100.00% (92.45–100.00)
49 to 55	39	35	4	89.74% (75.78–97.13)
56 to 62	33	33	0	100.00% (89.42–100.00)
≥63 (up to 120)	21	21	0	100.00% (83.89–100.00)
All samples ≥14 (up to 120)¹	240	235	5	97.92% (95.21–99.32)

¹ Only the last sample taken ≥ 14 days post-PCR of each patient is included in the sensitivity calculation.

PCR, polymerase chain reaction

Table 2b. Sensitivity results for the Elecsys Anti-SARS-CoV-2 S assay per site

Days post-PCR-positive test	Augsburg		Berlin		Heidelberg		Regensburg	
	N	Sensitivity (95% CI)	N	Sensitivity (95% CI)	N	Sensitivity (95% CI)	N	Sensitivity (95% CI)
0 to 6	3	33.33% (0.84–90.57)	23	60.87% (38.54–80.29)	18	55.56% (30.76–78.47)	0	N/A
7 to 13	4	100.00% (39.76–100.00)	34	85.29% (68.94–95.05)	11	81.82% (48.22–97.72)	0	N/A
≥ 14 (up to 120) ¹	88	100.00% (95.89–100.00)	41	100.00% (91.40–100.00)	78	98.72% (93.06–99.97)	33	87.88% (71.80–96.60)

¹ Only the last sample taken ≥ 14 days post-PCR of each patient is included in the sensitivity calculation.

CI, confidence interval; N, number of samples; N/A, not applicable; PCR, polymerase chain reaction

588 **Table 3. Specificity of the Elecsys Anti-SARS-CoV-2 S assay and other comparator assays**

Assay	Number of samples	Reactive samples	Non-reactive samples	Specificity (95% confidence intervals, 2-sided)
LIAISON SARS-CoV-2 S1/S2 IgG (GZ excl.) ¹	2033	24	2009	98.82% (98.25–99.24)
Elecsys Anti-SARS-CoV-2 S		1	2032	99.95% (99.73–100.00)
LIAISON SARS-CoV-2 S1/S2 IgG (GZ+)	2040	31	2009	98.48% (97.85–98.97)
Elecsys Anti-SARS-CoV-2 S		1	2039	99.95% (99.73–100.00)
ADVIA Centaur SARS-CoV-2 Total	928	121	807	86.96% (84.62–89.06)
Elecsys Anti-SARS-CoV-2 S		0	928	100.00% (99.60–100.00)
ARCHITECT SARS-CoV-2 IgG	2932	9	2923	99.69% (99.42–99.86)
Elecsys Anti-SARS-CoV-2 S		1	2931	99.97% (99.81–100.00)
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ excl.)	903	23	880	97.45% (96.20–98.38)
Elecsys Anti-SARS-CoV-2 S		0	903	100.00% (99.59–100.00)
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ+)	924	44	880	95.24% (93.66–96.52)
Elecsys Anti-SARS-CoV-2 S		0	924	100.00% (99.60–100.00)
EUROIMMUN Anti-SARS-CoV-2 IgA (GZ excl.)	895	38	857	95.75% (94.22–96.98)
Elecsys Anti-SARS-CoV-2 S		0	895	100.00% (99.59–100.00)
EUROIMMUN Anti-SARS-CoV-2 IgA (GZ+)	928	71	857	92.35% (90.45–93.98)
Elecsys Anti-SARS-CoV-2 S		0	928	100.00% (99.60–100.00)
iFlash-SARS-CoV-2 IgG	928	0	928	100.00% (99.60–100.00)
Elecsys Anti-SARS-CoV-2 S		0	928	100.00% (99.60–100.00)
iFlash-SARS-CoV-2 IgM	928	4	924	99.57% (98.90–99.88)
Elecsys Anti-SARS-CoV-2 S		0	928	100.00% (99.60–100.00)

589 ¹For antibody assays with a gray zone, two calculations were performed. In the first calculation, all gray zone
590 results were excluded from the analysis (GZ excl.) and in the second calculation these results were interpreted as
591 reactive (GZ+).

592 GZ, gray zone

593

594 **Table 4. Sensitivity of the Elecsys Anti-SARS-CoV-2 S assay and other comparator assays**

Assay	Days post-PCR- positive test	Total samples	Non-reactive samples	Sensitivity (95% confidence intervals, 2-sided)
ADVIA Centaur SARS-CoV-2 Total	0–6	18	8	55.56% (30.76–78.47)
			8	55.56% (30.76–78.47)
Elecsys Anti-SARS-CoV-2 S	7–13	11	2	81.82% (48.22–97.72)
			2	81.82% (48.22–97.72)
	≥ 14	77	4	94.81% (87.23–98.57)
			1	98.70% (92.98–99.97)
ARCHITECT SARS-CoV-2 IgG	0–6	18	9	50.00% (26.02–73.98)
			8	55.56% (30.76–78.47)
Elecsys Anti-SARS-CoV-2 S	7–13	11	2	81.82% (48.22–97.72)
			2	81.82% (48.22–97.72)
	≥ 14	77	10	87.01% (77.41–93.59)
			1	98.70% (92.98–99.97)
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ excl.) ¹	0–6	43	21	51.16% (35.46–66.69)
			18	58.14% (42.13–72.99)
Elecsys Anti-SARS-CoV-2 S	7–13	45	7	84.44% (70.54–93.51)
			7	84.44% (70.54–93.51)
	≥ 14	115	7	93.91% (87.86–97.52)
			2	98.26% (93.86–99.79)
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ+)	0–6	44	21	52.27% (36.69–67.54)
			19	56.82% (41.03–71.65)
Elecsys Anti-SARS-CoV-2 S	7–13	49	7	85.71% (72.76–94.06)
			7	85.71% (72.76–94.06)
	≥ 14	119	6	94.96% (89.35–98.13)
			1	99.16% (95.41–99.98)
EUROIMMUN Anti-SARS-CoV-2 IgA (GZ excl.)	0–6	44	18	59.09% (43.25–73.66)
			19	56.82% (41.03–71.65)
Elecsys Anti-SARS-CoV-2 S	7–13	49	4	91.84% (80.40–97.73)
			7	85.71% (72.76–94.06)

	≥ 14	118	3	97.46% (92.75–99.47)
			1	99.15% (95.37–99.98)
EUROIMMUN Anti-SARS-CoV-2 IgA			18	59.09% (43.25–73.66)
(GZ+)	0–6	44	19	56.82% (41.03–71.65)
	7–13	49	4	91.84% (80.40–97.73)
Elecsys Anti-SARS-CoV-2 S			7	85.71% (72.76–94.06)
	≥ 14	121	3	97.52% (92.93–99.49)
			1	99.17% (95.48–99.98)
iFlash-SARS-CoV-2 IgG			8	52.94% (27.81–77.02)
	0–6	17	7	58.82% (32.92–81.56)
Elecsys Anti-SARS-CoV-2 S			2	81.82% (48.22–97.72)
	7–13	11	2	81.82% (48.22–97.72)
	≥ 14	76	5	93.42% (85.31–97.83)
			0	100.00% (95.26–100.00)
iFlash-SARS-CoV-2 IgM			11	35.29% (14.21–61.67)
	0–6	17	7	58.82% (32.92–81.56)
Elecsys Anti-SARS-CoV-2 S			9	18.18% (2.28–51.78)
	7–13	11	2	81.82% (48.22–97.72)
	≥ 14	76	49	35.53% (24.88–47.34)
			0	100.00% (95.26–100.00)

595 ¹For antibody assays with a gray zone, two calculations were performed. In the first calculation, all gray zone
596 results were excluded from the analysis (GZ excl.) and in the second calculation these results were interpreted as
597 reactive (GZ+).
598 GZ, gray zone
599




Figure 1. Longitudinal antibody titers of all subjects. Concentration of anti-S SARS-CoV-2 antibodies, as measured by the Elecsys Anti-S SARS-CoV-2 S immunoassay, over time (days 0 to 78) in sequential samples from all study sites. Each grey circle represents a different data point, with darker circles representing overlapping data points. The solid blue line represents the combined curve and the blue dashed lines represent the upper and lower confidence limits. The red dashed line indicates the assay cutoff limit (0.80 U/mL).